<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478490</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-005</org_study_id>
    <nct_id>NCT01478490</nct_id>
  </id_info>
  <brief_title>To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol</brief_title>
  <official_title>An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare blood and urine concentrations of mirabegron (YM178) in healthy
      poor or extensive metabolizers for CYP2D6 and to evaluate if blood levels of metoprolol
      change whilst being dosed at the same time with daily miragebron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open label, single center study. All subjects are genotyped for CYP2D6 before
      the study. Genotype expression is confirmed by dextromethorphan phenotyping.

      Part I: The pharmacokinetic profile of a single dose of YM178 is compared in 8 healthy male
      subjects genotyped and phenotyped as poor metaboliser (PM) for CYP2D6 and in 8 healthy male
      subjects genotyped and phenotyped as extensive metaboliser (EM) for CYP2D6.

      Part II: The effect of YM178 on the model substrate of CYP2D6 metoprolol is evaluated, using
      a cross-over design, in 12 healthy male subjects genotyped and phenotyped as EM for CYP2D6.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of mirabegron assessed by plasma concentration</measure>
    <time_frame>Pre-dose until 72 hours after dosing</time_frame>
    <description>Primary outcome measure for Part 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of metoprolol assessed by plasma concentration</measure>
    <time_frame>Pre-dose until 48 hours after dosing</time_frame>
    <description>Primary outcome measure for Part 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron, poor metabolizers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron, extensive metabolizers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron/metoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm 1A</arm_group_label>
    <arm_group_label>Treatment Arm 1B</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Part I:

          -  Subject genotyped and phenotyped for CYP2D6

          -  Body weight between 60 and 100 kg and Body Mass Index less than or equal to 30 kg/m2

        For Part II:

          -  Subject genotyped and phenotyped as extensive metaboliser for CYP2D6

          -  Body weight between 60 and 100 kg and Body Mass Index less than or equal to 30 kg/m2

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to β-adrenergic receptor agonists or constituents
             of the formulations used

          -  Any clinically significant history of asthma, eczema, any other allergic condition or
             previous severe hypersensitivity to any drug

          -  Any clinically significant history of upper gastrointestinal symptoms (such as nausea,
             vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to
             admission to the Research Unit

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,
             dermatological, psychiatric or metabolic

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  QTc intervals of &gt;430 msec

          -  Abnormal pulse rate measurement (&lt;40 or &gt;90 bpm) taken by manual counting at the
             pre-study visit after subject has been resting in supine position for 5 min

          -  Abnormal blood pressure measurements taken at the pre-study visit after subject has
             been resting in supine position for 5 min as follows: systolic blood pressure &lt;95 or
             &gt;160 mmHg; diastolic blood pressure &lt;40 or &gt;95 mmHg

          -  Positive orthostatic test at screening i.e. any symptoms of dizziness,
             light-headedness etc. and/or a fall of ≥ 20 mmHg in systolic blood pressure after 2
             min standing (preceded by 5 min. supine rest) and/or an increase in pulse rate of ≥ 20
             bpm

          -  Regular use of any prescribed or OTC drugs except paracetamol up to 3 g/day, in the 4
             weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks
             prior to admission to the Research Unit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Bio-Research Group B.V., Zuidlaren, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International (former Pharma Bio-Research)</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=798</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.</citation>
    <PMID>23728524</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics,</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Metoprolol</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

